Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment

While polyphenolic compounds have many health benefits, the potential development of polyphenols for the prevention/treatment of neurological disorders is largely hindered by their complexity as well as by limited knowledge regarding their bioavailability, metabolism, and bioactivity, especially in the brain. We recently demonstrated that dietary supplementation with a specific grape-derived polyphenolic preparation (GP) significantly improves cognitive function in a mouse model of Alzheimer's disease (AD). GP is comprised of the proanthocyanidin (PAC) catechin and epicatechin in monomeric (Mo), oligomeric, and polymeric forms. In this study, we report that following oral administration of the independent GP forms, only Mo is able to improve cognitive function and only Mo metabolites can selectively reach and accumulate in the brain at a concentration of ∼400 nm. Most importantly, we report for the first time that a biosynthetic epicatechin metabolite, 3′-O-methyl-epicatechin-5-O-β-glucuronide (3′-O-Me-EC-Gluc), one of the PAC metabolites identified in the brain following Mo treatment, promotes basal synaptic transmission and long-term potentiation at physiologically relevant concentrations in hippocampus slices through mechanisms associated with cAMP response element binding protein (CREB) signaling. Our studies suggest that select brain-targeted PAC metabolites benefit cognition by improving synaptic plasticity in the brain, and provide impetus to develop 3′-O-Me-EC-Gluc and other brain-targeted PAC metabolites to promote learning and memory in AD and other forms of dementia.

[1]  P. Milbury,et al.  Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. , 2010, Journal of agricultural and food chemistry.

[2]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[3]  D. Teplow,et al.  Grape-Derived Polyphenolics Prevent Aβ Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[4]  D. Riesner,et al.  Single particle detection of Abeta aggregates associated with Alzheimer's disease. , 2007, Biochemical and biophysical research communications.

[5]  Wei Zhao,et al.  Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.

[6]  Gene W. Yeo,et al.  Plant-Derived Flavanol (−)Epicatechin Enhances Angiogenesis and Retention of Spatial Memory in Mice , 2007, The Journal of Neuroscience.

[7]  A. Fagan,et al.  Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease , 2006, Neurobiology of Disease.

[8]  W. Feng Metabolism of green tea catechins: an overview. , 2006, Current drug metabolism.

[9]  C. Rice-Evans,et al.  Distribution of [3H]trans-resveratrol in rat tissues following oral administration , 2006, British Journal of Nutrition.

[10]  David Morgan,et al.  Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice , 2005, The Journal of Neuroscience.

[11]  C. Auger,et al.  The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats , 2005, British Journal of Nutrition.

[12]  R. Lamuela-Raventós,et al.  Rapid liquid chromatography tandem mass spectrometry assay to quantify plasma (-)-epicatechin metabolites after ingestion of a standard portion of cocoa beverage in humans. , 2005, Journal of agricultural and food chemistry.

[13]  P. Hof,et al.  Caloric restriction attenuates β‐amyloid neuropathology in a mouse model of Alzheimer's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  O. Vitolo,et al.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.

[15]  C. Rice-Evans,et al.  Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. , 2002, Free radical biology & medicine.

[16]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[17]  Eric R Kandel,et al.  CREB1 Encodes a Nuclear Activator, a Repressor, and a Cytoplasmic Modulator that Form a Regulatory Unit Critical for Long-Term Facilitation , 1998, Cell.

[18]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[19]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[20]  R. Dixon,et al.  Fractionation of Grape Seed Proanthocyanidins for Bioactivity Assessment , 2011 .